Personalized medicine in oncology: the future is now
Personalized medicine in oncology: the future is now
复制标题
DOI：
10.1038/nrd3181
复制
发表时间：
2010-05-01
影响因子：
120.1
通讯作者：
Schilsky, Richard L.
中科院分区：
文献类型：
--
作者：
Schilsky, Richard L.
癌症化疗正在从损伤肿瘤和正常细胞的非特异性细胞毒性药物向更特异性的药物和免疫治疗方法演变。靶向药物针对癌细胞的独特分子特征，免疫治疗剂调节肿瘤免疫反应;这两种方法都旨在以更低的毒性产生更大的有效性。在生物标志物定义的人群中开发和使用此类药物，可以实现比以前更个性化的癌症治疗方法，并有可能降低癌症护理的成本。
Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both tumour and normal cells to more specific agents and immunotherapy approaches. Targeted agents are directed at unique molecular features of cancer cells, and immunotherapeutics modulate the tumour immune response; both approaches aim to produce greater effectiveness with less toxicity. The development and use of such agents in biomarker-defined populations enables a more personalized approach to cancer treatment than previously possible and has the potential to reduce the cost of cancer care.